A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.
Welcome to OncologyTube.com, where we bring you the latest in oncology research and treatment breakthroughs. In this video, we feature an insightful intervie…
At the 66th ASH Annual Meeting and Exposition, Rodriguez presented results from Arm C of Kilimanjaro (NCT05259839), an open-label, phase I dose-escalation and expansion trial…
An abstract is unavailable.
Filippo Pietrantonio, MD, discusses updated results from the phase 1b/2 OrigAMI-1 trial, which showed that amivantamab with or without chemotherapy demonstrated durable antitumor activity among…
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a…
Welcome! You are invited to join a webinar: Virtual Tumor Board: GI Malignancy and Inflammatory Bowel Disease . After registering, you will receive a confirmation…
Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and…
The 5th Oxford Myeloma workshop took place on January 30-31, 2025 in Oxford, United Kingdom and brought together clinicians, academic myeloma researchers, and patient advocates…
The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.
